NCT00083876View on ClinicalTrials.gov

D.T. PACE Versus High Dose Melphalan and Autologous Transplant in Patients With Previously Treated Multiple Myeloma

PHASE3CompletedINTERVENTIONAL

Enrollment

500

Participants

Timeline

Start Date

September 30, 1998

Study Completion Date

November 30, 2007

Conditions

Multiple Myeloma

Interventions

DRUG

Thalidomide

Trial Locations (1)

72205

University of Arkansas for Medical Sciences/MIRT, Little Rock

Sponsors

Collaborators (1)

Celgene Corporation

All Listed Sponsors

collaborator

Celgene Corporation

INDUSTRY

lead

University of Arkansas

OTHER

NCT00083876 - D.T. PACE Versus High Dose Melphalan and Autologous Transplant in Patients With Previously Treated Multiple Myeloma | Biotech Hunter | Biotech Hunter